HCV protease inhibitor
Velpatasvir is a second-generation NS5A inhibitor that inhibits hepatitis C viral replication through acting on the crucial “membranous web” that facilitates RNA replication.
Velpatasvir 25 mg
£97.00
Target: NS5A
Chemical name: Carbamic acid, N-[(1R)-2-[(2S,4S)-2-[5-[1,11-dihydro-2-[(2S,5S)-1-[(2S)-2-[(methoxycarbonyl)amino]-3-methyl-1-oxobutyl]-5-methyl-2-pyrrolidinyl][2]benzopyrano[4′,3′:6,7]naphth[1,2-d]imidazol-9-yl]-1H-imidazol-2-yl]-4-(methoxymethyl)-1-pyrrolidinyl]-2-oxo-1-phenylethyl]-, methyl ester
Formula: C49H54N8O8
Molecular weight: 883
Purity: 99.38 %
Solubility: 100 mg/mL (DMSO), 100 mg/mL (ethanol), 100 mg/mL (water)
Size: 25 mg
Storage: 3 years -20°C powder, 2 years -80°C in solvent
In vitro:
Velpatasvir (VEL, GS-5816) is a novel pan-genotypic hepatitis C virus (HCV) nonstructural protein 5A (NS5A) inhibitor with activity against genotype 1 (GT1) to GT6 HCV replicons. It is a selective inhibitor of HCV RNA replication with mean 50% effective concentrations (EC50s) against GT1 to GT6 of 6 to 130 pM
References:
[1] Mir F, et al. Drug Des Devel Ther. 2017, 11:497-502.